http://www.ceregene.com/science_ocular.asp
Ceregene's Treatment Strategy for Ocular Diseases
Ceregene is using its novel gene delivery technology to deliver the gene for neurotrophic factor 4 (NT4) to the retina. This product, CERE-140, is still in nonclinical (not yet testing in humans) stages of development, but initial animal studies injecting CERE-140 into the large chamber of the eye, have salvaged and improved the function of photoreceptors in animal models of RP. CERE-140 is thus intended to enhance the function and prevent loss of photoreceptor cells in the retina, restoring and preserving sight in patients with RP. A major advantage of our approach is that it should be feasible to treat all cases of RP, independent of which different genetic mutation is responsible for the disease. Moreover, a single dosing session with CERE-140 may be sufficient to maintain and possibly restore sight, indefinitely.
动物实验鼓舞人心，该技术可以有效保持视力，可能恢复视力。作者: 凤凰涅盘 时间: 2012-7-24 22:34
